ReviewFrontiers in endocrinology2026
Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure arising in cardiovascular-kidney-metabolic (CKM) syndrome, hereafter referred to as CKM-related heart failure (CKM-HF), is increasingly understood as the cardiac expression of multisystem endocrine and metabolic stress rather than as an isolated myocardial disorder. In this narrative review, we examine how kidney, bone, adipose tissue, gut, pancreas, vasculature, and myocardium communicate through maladaptive hormonal and metabolic signals, with particular emphasis on heart failure with preserved ejection fraction (HFpEF). We position the fibroblast growth factor 23 (FGF23)-Klotho axis as a candidate organizing framework for mineral endocrine stress in diabetic kidney disease and chronic kidney disease. Human observational studies associate higher circulating FGF23 and altered Klotho biology with adverse cardiovascular phenotypes, whereas preclinical studies provide mechanistic plausibility for links to cardiac hypertrophy and fibrosis. However, current evidence does not establish that elevated FGF23 directly causes cardiac remodeling in humans. We examine insulin resistance, adipose dysfunction, RAAS activation, anemia, and gut-derived metabolites selectively as modifiers, competing pathways, or confounders that shape the interpretation of FGF23-Klotho biology in CKM-related heart failure. Established cardiometabolic therapies are discussed according to their proven clinical effects and as modifiers of the context in which FGF23 and soluble Klotho are interpreted; their efficacy is not considered evidence of FGF23-Klotho pathway engagement or mediation. An FGF23-Klotho-centered CKM-HF framework may support research phenotyping, prospective biomarker validation, and mechanism-based trial design. However, the proposed phenotype remains unvalidated, circulating FGF23 and soluble Klotho are not established for routine clinical use, and their incremental value beyond conventional kidney, mineral, cardiac, and imaging markers remains unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.